Chinook Therapeutics

Clinical-stage biopharmaceutical company focused on developing precision medicines for kidney diseases. Acquired by Novartis in 2023 for $3.5 billion.

Location
Seattle, Washington & Vancouver, British Columbia
Founded
2019
Investors
1
Categories
biotech, nephrology, kidney-disease, therapeutics, autoimmune

Investors

NameLocationTypeStagesPortfolio
Apple Tree PartnersNew York, USAbiotech-focused
series-aseries-b+2
23